Details for New Drug Application (NDA): 205727
✉ Email this page to a colleague
NDA 205727 describes SODIUM POLYSTYRENE SULFONATE, which is a drug marketed by Belcher, Chartwell Rx, Citrusphrma, Cmp Pharma Inc, Epic Pharma Llc, Nuvo Pharms Inc, Pai Holdings Pharm, Upsher Smith Labs, Ani Pharms, Hikma, Morton Grove, and Roxane, and is included in twelve NDAs. It is available from nine suppliers. Additional details are available on the SODIUM POLYSTYRENE SULFONATE profile page.
The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
Summary for 205727
| Tradename: | SODIUM POLYSTYRENE SULFONATE |
| Applicant: | Belcher |
| Ingredient: | sodium polystyrene sulfonate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 205727
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SODIUM POLYSTYRENE SULFONATE | sodium polystyrene sulfonate | POWDER;ORAL, RECTAL | 205727 | ANDA | Belcher Pharmaceuticals, LLC | 62250-660 | 62250-660-23 | 454 g in 1 BOTTLE (62250-660-23) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL, RECTAL | Strength | 454GM/BOT | ||||
| Approval Date: | Feb 23, 2016 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
